CLINICAL EVALUATION OF REPERFUSION IN ST ELEVATION MYOCARDIAL INFARCTION WITH NON- INVASIVE MARKERS FOLLOWING THROMBOLYSIS WITH STREPTOKINASE VERSUS TENECTEPLASE.

Author:

Shah Shaila1,Sukhwani Kalpesh2,Prajapati Vipul3,V Sahasranam K.4

Affiliation:

1. MD Associate professor, Dept. of Medicine GCS Medical College, Ahmedabad, Gujarat India. 380025.

2. MD Ex-Assistant Professor, Dept. of Medicine.

3. MD Assistant Professor, Dept of Medicine

4. DM Cardiology Chief of Medical Services and Senior Consultant Cardiologist Baby Memorial Hospital, Kozhikode, Kerala, India.

Abstract

Background: Acute ST elevation myocardial infarction occurs due to an occluded coronary artery and can cause death of the patient. The best modality of treating an occluded coronary artery is a primary PCI. Thrombolytic therapy can however render similar results if administered within 2 hours of symptom onset. The concept of pre-hospital thrombolysis is being advocated in the face of current guidelines. Streptokinase (SK) is the most inexpensive of available thrombolytics but is brin non-specic, antigenic and has to be given as an infusion. Reteplase and Tenecteplase(TNK) are brin specic, non- antigenic and can be given as bolus doses making them good agents for prehospital thrombolysis. Aims: We aimed to study reperfusion after thrombolysis with streptokinase vs tenectepalse based on non-invasive criteria.Methods:98 patients were enrolled in this study at a tertiary care centre in a medical college in Southern India between August 2014 to August 2015. This was a nonrandomised quasi-experimental study. 54 patients received streptokinase and 44 received tenecteplase in the study. Results: The reperfusion rate was 46.4% with streptokinase(SK) and 54.3% with Tenecteplase(TNK). Tenecteplase proved to be a better agent for patients aged more than 74 years and for patients who presented later than 2 hours. The difference between SK and TNK was not found to be signicant. Conclusion: Tenecteplase is not superior to Streptokinase in achieving reperfusion in STEMI.

Publisher

World Wide Journals

Reference24 articles.

1. Dalal JJ, Alexander T, Banerjee PS, Dayasagar V, lyengar SS, Kerkar PG et al. Cardiocare STEMI experts. 2013 consensus statement for early reperfusion and pharmaco-invasive approach in patients presenting with chest pain diagnosed as STEMI (ST elevation myocardial infarction) in an Indian setting. J Assoc Physicians India. 2014 Jun;62(6):473-83.

2. SS Iyengar, Girish Godbole. Thrombolysis in The Era of intervention. Supplement to JAPI. December 2011;59:26-30

3. Bonnefoy E, Steg PG, Boutitie F, Dubien PY, Lapostolle F, Roncalli J et al. CAPTIM Investigators. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J. 2009 Jul;30(13):1598-606.

4. Gurpreet Singh Wander, Shibba Takkar Chhabra. Critical Analysis of various drugs used for thrombolytic therapy in acute myocardial infarction. Medicine update 2013: 109-116

5. Dalal J, Sahoo PK, Singh RK, Dhall A, Kapoor R, Krishnamurthy A et al. Role of thrombolysis in reperfusion therapy for management of AMI: Indian scenario. Indian Heart J. 2013 Sep-Oct;65(5):566-85.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3